Singapore markets close in 2 minutes
  • Straits Times Index

    3,240.62
    -3.93 (-0.12%)
     
  • Nikkei

    28,162.83
    -120.20 (-0.42%)
     
  • Hang Seng

    17,297.94
    -275.64 (-1.57%)
     
  • FTSE 100

    7,437.28
    -49.39 (-0.66%)
     
  • BTC-USD

    16,244.19
    -295.27 (-1.79%)
     
  • CMC Crypto 200

    380.90
    -1.76 (-0.46%)
     
  • S&P 500

    4,026.12
    -1.14 (-0.03%)
     
  • Dow

    34,347.03
    +152.93 (+0.45%)
     
  • Nasdaq

    11,226.36
    -58.94 (-0.52%)
     
  • Gold

    1,757.80
    +3.80 (+0.22%)
     
  • Crude Oil

    74.16
    -2.12 (-2.78%)
     
  • 10-Yr Bond

    3.6910
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,486.54
    0.00 (0.00%)
     
  • Jakarta Composite Index

    7,017.36
    -35.79 (-0.51%)
     
  • PSE Index

    6,681.47
    +74.53 (+1.13%)
     

Lonza's first-half core EBITDA gains 16.5%

FILE PHOTO: Logo of Swiss pharmaceutical group Lonza is seen in Basel

By Ludwig Burger

(Reuters) -Swiss drug contract manufacturer Lonza said first-half core earnings gained 16.5% on strong demand from biopharmaceutical companies.

First-half core earnings - adjusted for interest, tax, depreciation and amortisation - (EBITDA) rose to 987 million Swiss francs ($1.02 billion), it said in a statement on Friday, beating an analyst consensus of about 940 million francs.

For this year, Lonza said it was still targeting "low to mid-teens" sales growth, when excluding currency swings, as well as an improvement in the core EBITDA margin that is consistent with a 2024 goal of 33%-35%, up from 30.8% in 2021.

The company is in a multi-year investment push to assist drug developers as they bet on new therapeutic proteins as well as cell and gene therapies. Under the plan, Lonza earlier this month announced a 500 million franc investment in Switzerland to fill biotech drugs into vials.

The company, which is a key supplier of vaccine maker Moderna, is banking on long-term growth in the biopharmaceuticals sector well beyond the pandemic.

(Reporting by Ludwig Burger, Editing by Miranda Murray)